The NCCN added MammaPrint + BluePrint to the Clinical Practice Guidelines in Oncology for the identification of a subset of hormone receptor positive, HER2-negative early-stage breast cancer patients most likely to benefit from anthracycline-based chemotherapy.
The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.
